Literature DB >> 24065449

An immunohistochemical panel for reliable differentiation of salivary duct carcinoma and mucoepidermoid carcinoma.

Randall T Butler1, Matthew E Spector, Dafydd Thomas, Andrew S McDaniel, Jonathan B McHugh.   

Abstract

Salivary duct carcinoma is a highly aggressive salivary gland malignancy that may be misdiagnosed as high-grade mucoepidermoid carcinoma. We utilized tissue microarrays with 78 examples of mucoepidermoid carcinoma and 47 salivary duct carcinomas to evaluate the utility of an immunohistochemical panel consisting of androgen receptor, Her2/neu, p63, and cytokeratin 5/6 in distinguishing these entities. Among all cases in the cohorts, androgen receptor was highly specific for salivary duct carcinoma, while cytokeratin 5/6 and p63 were specific for mucoepidermoid carcinoma. While the rate of unequivocal Her2/neu overexpression among the salivary duct carcinomas was low (8.9 %), discrimination of salivary duct carcinoma was enhanced when this marker was used in combination with androgen receptor due to profound sensitivity. The immunohistochemical panel was particularly efficacious at distinguishing the problematic subset of high-grade mucoepidermoid carcinomas from salivary duct carcinoma. Utilization of this set of immunohistochemical markers allows reliable differentiation of salivary duct and mucoepidermoid carcinoma, a distinction with important prognostic and therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24065449      PMCID: PMC4022941          DOI: 10.1007/s12105-013-0493-5

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  41 in total

1.  Mucoepidermoid carcinoma of the salivary glands--clinical review of 42 cases.

Authors:  Horst Kokemueller; Niels Brueggemann; Gwen Swennen; André Eckardt
Journal:  Oral Oncol       Date:  2005-01       Impact factor: 5.337

2.  Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases.

Authors:  Michael Jaehne; Kerstin Roeser; Thorsten Jaekel; Jan David Schepers; Natalie Albert; Thomas Löning
Journal:  Cancer       Date:  2005-06-15       Impact factor: 6.860

3.  Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.

Authors:  Michelle D Williams; Dianna B Roberts; Merrill S Kies; Li Mao; Randal S Weber; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

4.  Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading.

Authors:  M S Brandwein; K Ivanov; D I Wallace; J J Hille; B Wang; A Fahmy; C Bodian; M L Urken; D R Gnepp; A Huvos; H Lumerman; S E Mills
Journal:  Am J Surg Pathol       Date:  2001-07       Impact factor: 6.394

5.  Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma.

Authors:  A Felix; A K El-Naggar; M F Press; N G Ordonez; I Fonseca; S L Tucker; M A Luna; J G Batsakis
Journal:  Hum Pathol       Date:  1996-06       Impact factor: 3.466

6.  Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.

Authors:  Silvana Di Palma; Roderick H W Simpson; Caterina Marchiò; Alena Skálová; Marco Ungari; Ann Sandison; Stephen Whitaker; Suzanne Parry; Jorge S Reis-Filho
Journal:  Histopathology       Date:  2012-10       Impact factor: 5.087

7.  Salivary duct carcinoma--a highly aggressive salivary gland tumour with overexpression of c-erbB-2.

Authors:  H B Hellquist; M G Karlsson; C Nilsson
Journal:  J Pathol       Date:  1994-01       Impact factor: 7.996

8.  Salivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature.

Authors:  Jairam Krishnamurthy; Devi Mukkai Krishnamurty; John J Baker; Weining Zhen; Daniel Lydiatt; Apar Kishor Ganti
Journal:  Head Neck       Date:  2013-06-14       Impact factor: 3.147

Review 9.  Salivary duct carcinoma. Part I. A clinicopathologic evaluation and DNA image analysis of 13 cases with review of the literature.

Authors:  L Barnes; U Rao; J Krause; L Contis; A Schwartz; P Scalamogna
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1994-07

10.  Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry.

Authors:  A Skálová; I Stárek; T Vanecek; V Kucerová; L Plank; P Szépe; S Di Palma; I Leivo
Journal:  Histopathology       Date:  2003-04       Impact factor: 5.087

View more
  12 in total

1.  Salivary Duct Carcinoma and Invasive Ductal Carcinoma of the Breast: A Comparative Immunohistochemical Study.

Authors:  Jalal B Jalaly; Souzan Sanati; Rebecca D Chernock; Dikson G Dibe; Samir K El-Mofty
Journal:  Head Neck Pathol       Date:  2018-01-04

2.  Metastatic Salivary Ductal Carcinoma to the Mastoid Segment of the Facial Nerve.

Authors:  Joshua E Fabie; Jonathan L Hatch; Ashley W Cross; Samuel L Oyer; David M Neskey; Theodore R McRackan
Journal:  Otol Neurotol       Date:  2018-09       Impact factor: 2.311

Review 3.  Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment.

Authors:  Masato Nakaguro; Yuichiro Tada; William C Faquin; Peter M Sadow; Lori J Wirth; Toshitaka Nagao
Journal:  Cancer Cytopathol       Date:  2020-05-18       Impact factor: 5.284

4.  Expression of Hormone Receptors and HER-2 in Benign and Malignant Salivary Gland Tumors.

Authors:  Nhu Thuy Can; Mark W Lingen; Heather Mashek; James McElherne; Renee Briese; Carrie Fitzpatrick; Annemieke van Zante; Nicole A Cipriani
Journal:  Head Neck Pathol       Date:  2017-07-05

Review 5.  Salivary mucoepidermoid carcinoma revisited.

Authors:  Andrés Coca-Pelaz; Juan P Rodrigo; Asterios Triantafyllou; Jennifer L Hunt; Alessandra Rinaldo; Primož Strojan; Missak Haigentz; William M Mendenhall; Robert P Takes; Vincent Vander Poorten; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-26       Impact factor: 2.503

6.  VDR in salivary gland homeostasis and cancer.

Authors:  Kara A DeSantis; Samantha L Robilotto; Mark Matson; Noor M Kotb; Cathryn M Lapierre; Zenab Minhas; Alana A Leder; Khushbakht Abdul; Emily M Facteau; JoEllen Welsh
Journal:  J Steroid Biochem Mol Biol       Date:  2020-01-17       Impact factor: 4.292

7.  Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.

Authors:  Inga Grünewald; Claudia Vollbrecht; Jeannine Meinrath; Moritz F Meyer; Lukas C Heukamp; Uta Drebber; Alexander Quaas; Dirk Beutner; Karl-Bernd Hüttenbrink; Eva Wardelmann; Wolfgang Hartmann; Reinhard Büttner; Margarete Odenthal; Markus Stenner
Journal:  Oncotarget       Date:  2015-07-20

Review 8.  Androgen Receptor Signaling in Salivary Gland Cancer.

Authors:  Martin G Dalin; Philip A Watson; Alan L Ho; Luc G T Morris
Journal:  Cancers (Basel)       Date:  2017-02-08       Impact factor: 6.639

9.  Mammary analogue secretory carcinoma of salivary glands: diagnostic pitfall with distinct immunohistochemical profile and molecular features.

Authors:  Oliver Bissinger; Carolin Götz; Andreas Kolk; Henning A Bier; Abbas Agaimy; Henning Frenzel; Sven Perner; Julika Ribbat-Idel; Klaus Dietrich Wolff; Wilko Weichert; Caroline Mogler
Journal:  Rare Tumors       Date:  2017-10-03

Review 10.  2021 Update on Diagnostic Markers and Translocation in Salivary Gland Tumors.

Authors:  Malin Tordis Meyer; Christoph Watermann; Thomas Dreyer; Süleyman Ergün; Srikanth Karnati
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.